Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal-dominant Alzheimer's disease

Schultz, Stephanie; Shirzadi, Zahra P.; Schultz, Aaron; Liu, Lei D.; Fitzpatrick, Colleen; McDade, Eric R.; Barthelemy, Nicolas; Renton, Alan; Esposito, Bianca; Joseph-Mathurin, Nelly; Cruchaga, Carlos D.; Chen, Charles; Goate, Alison; Allegri, Ricardo Francisco; Benzinger, Tammie L. S.; Berman, Sarah C.; Chui, Helena M.; Fagan, Anne R.; Farlow, Martin C.; Fox, Nick A.; Gordon, Brian S.; Day, Gregory R.; Graff-Radford, Neill J.; Hassenstab, Jason J.; Hanseeuw, Bernard; Hofmann, Anna R.; Jack Jr, Clifford R.; Jucker, Mathias M.; Karch, Celeste A.; Koeppe, Robert; Lee, Jae-Hong I.; Levey, Allan; Levin, Johannes N.; Martins, Ralph; Mori, Hiroshi C.; Morris, John; Noble, James J.; Perrin, Richard; Rosa-Neto, Pedro P.; Salloway, Stephen; Sanchez-Valle, Raquel R.; Schofield, Peter; Xiong, Chengjie A.; Johnson, Keith J.; Bateman, Randall A.; Sperling, Reisa P. und Chhatwal, Jasmeer (2023): Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal-dominant Alzheimer's disease. In: Aging Cell, Bd. 22, Nr. 8, e13871

Abstract

Although pathogenic variants in PSEN1 leading to autosomal-dominant Alzheimer disease (ADAD) are highly penetrant, substantial interindividual variability in the rates of cognitive decline and biomarker change are observed in ADAD. We hypothesized that this interindividual variability may be associated with the location of the pathogenic variant within PSEN1. PSEN1 pathogenic variant carriers participating in the Dominantly Inherited Alzheimer Network (DIAN) observational study were grouped based on whether the underlying variant affects a transmembrane (TM) or cytoplasmic (CY) protein domain within PSEN1. CY and TM carriers and variant non-carriers (NC) who completed clinical evaluation, multimodal neuroimaging, and lumbar puncture for collection of cerebrospinal fluid (CSF) as part of their participation in DIAN were included in this study. Linear mixed effects models were used to determine differences in clinical, cognitive, and biomarker measures between the NC, TM, and CY groups. While both the CY and TM groups were found to have similarly elevated A beta compared to NC, TM carriers had greater cognitive impairment, smaller hippocampal volume, and elevated phosphorylated tau levels across the spectrum of pre-symptomatic and symptomatic phases of disease as compared to CY, using both cross-sectional and longitudinal data. As distinct portions of PSEN1 are differentially involved in APP processing by gamma-secretase and the generation of toxic beta-amyloid species, these results have important implications for understanding the pathobiology of ADAD and accounting for a substantial portion of the interindividual heterogeneity in ongoing ADAD clinical trials.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin > Munich Cluster for Systems Neurology (SyNergy)
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• Sprache: Englisch
• DFG: Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 390857198